
ABOUT SAMSUNG BIOLOGICS
Samsung Biologics is a full-service provider offering development and cGMP manufacturing services. We deliver a broad range of services from development and manufacturing to fill and finish, covering both clinical molecules and commercial products. Established in April 2011, Samsung Biologics will transform the global healthcare industry over the next decade through our quality, technology and innovation. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services (characterization, comparability, IPC, lot release & stability), and clinical and commercial bulk cGMP manufacturing of drug substance and drug product. We also provide quality assurance and quality control services, as well as worldwide regulatory compliance standards & support for our customers. We are centrally located in the heart of Asia, within 20 minutes of Incheon International Airport.
CONTACT INFORMATION
Samsung Biologics
300 Songdo Bio Way, Yeonsu-gu
Incheon, 21987
KOREA, REPUBLIC OF
Phone: +82 32 455 3114
Contact: Jinyong Kim
BROCHURES
- Link Your Antibody To Its Fullest Potential
- CDO Services: Agile. Flexible. Focused On You.
- Trusted End-To-End CDMO Partner For Your Journey
- Why Samsung Biologics?
- Antibody Drug Conjugates: Link Your Antibody To Its Fullest Potential
- Super Plant 4
- Plant 5 — Dream Plant: Within Your Reach. Built For Your Success.
- Ensure Success From An Early Stage: DEVELOPICK™
- The Power Of One: mRNA Services
- Customized CMC Solutions
- Leveraging Proprietary CDO Platforms
- Aseptic Fill/Finish Service
- The Choice For Your Next Dual-Specificity Therapeutics: S-DUAL™
- Capacity To Secure Your Success
FEATURED ARTICLES
- Enabling Digital Twins With Computational Fluid Dynamics Modeling
- Optimizing Bioprocesses Using Functional DOE
- A 5-Factor Framework For Successful CMO Partnership
- Mitigating Early Development Risks
- Improving Therapeutic Protein Efficacy Through Charge Profile Adjustment
- Leveraging Optimized Transient Expression For Material Generation And Early Stage Insight
- Embracing Quality-By-Design For Enhanced Development Strategies
- Streamlining Single-Use Assemblies In The Bulk-Fill Step Of Downstream Processing
- Reducing ADC Timelines With Integrated Development And Manufacturing
- Accelerating The Development And Production Of High-Quality bsAbs
- Optimizing Sialic Acid Clone Screening
- Addressing And Adapting To Evolving mRNA Market Trends
- β-Glucan As A Process-Related Impurity In Biopharmaceuticals
- Monoclonal Antibody Manufacturing: Build Or Outsource?
- Biopharma Tech Transfer: Facility Fit And Process Gap Assessments
- Choose A Partner That Integrates Market Intelligence For Aseptic Fill/Finish
- Critical Success Factors For Cell Line Development
- Beyond COVID-19: How Localization Strengthens Supply Chains
- The Challenges Of Biopharmaceutical Quality
- Why Choosing The Right CDMO Partner Is Essential In Today's Market
WEBINARS
- Introducing 2 New Highly Effective ADC Payloads For Cancer Therapeutics
- Navigating Challenges During Formulation Development
- Formulation Considerations For The Development Of High Concentration Biopharmaceuticals
- Harnessing Analytical Development To Empower Process Development
- Downstream Strategies To Accelerate Preclinical Development Timelines
- Enhancing Quality By Employing Cell Line Replacement, Process Optimization
- Key Considerations When Outsourcing An Aseptic Fill/Finish Project To A CMO Partner
- What To Consider In Selecting The Best Cell Line To Accelerate The Timeline To IND
- Biopharmaceutical Process Characterization
- Accelerated Tech Transfer For A COVID-19 Program
- Continuous Manufacturing: Challenges, Advantages Of N-1 Perfusion
- All Eyes On mRNA: Addressing Key Insights Into The Next Blockbuster
- Get To IND Faster
- How COVID-19 Is Redefining Drug Development And Manufacturing